-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On July 19, Jiuzhitang issued an announcement stating that the clinical trial application for the innovative drug YB209 developed by its subsidiary, Youbo Pharmaceutical, was approved by the FDA and was intended to be used for the prevention and treatment of venous thrombosis
Thromboembolic diseases (such as ischemic stroke, coronary heart disease, deep vein thrombosis, etc.
In the past four decades, anticoagulant drug research has made remarkable achievements in improving pharmacodynamic properties and oral administration, but it is still in the process of research and development in reducing bleeding tendency
YB209 is a new class 1 chemical drug.
Up to now, the project has obtained 17 patent authorization certificates distributed in 8 countries